Tactile Systems Technology Inc TCMD
We take great care to ensure that the data presented and summarized in this overview for TACTILE SYSTEMS TECHNOLOGY INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TCMD
View all-
Black Rock Inc. New York, NY2.43MShares$44.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.31MShares$42.3 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY1.93MShares$35.4 Million1.45% of portfolio
-
Paradigm Capital Management Inc1.66MShares$30.4 Million1.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$27.1 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M889KShares$16.3 Million0.01% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL885KShares$16.2 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX834KShares$15.2 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT727KShares$13.3 Million0.05% of portfolio
-
Royce & Associates LP613KShares$11.2 Million0.09% of portfolio
Latest Institutional Activity in TCMD
Top Purchases
Top Sells
About TCMD
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at TCMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2024
|
Sherri Lee Ferstler Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
1,550
-3.84%
|
$20,150
$13.07 P/Share
|
|
Aug 07
2024
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,959
+39.71%
|
-
|
|
May 16
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,041
-4.73%
|
$39,533
$13.68 P/Share
|
|
May 08
2024
|
William W Burke Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+22.65%
|
-
|
|
May 08
2024
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
2,500
-9.0%
|
$35,000
$14.06 P/Share
|
|
May 08
2024
|
Boyd Vindell Washington Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+35.32%
|
-
|
|
May 08
2024
|
Carmen B Volkart Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+32.62%
|
-
|
|
May 08
2024
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+24.23%
|
-
|
|
May 08
2024
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+20.64%
|
-
|
|
May 08
2024
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+23.73%
|
-
|
|
May 08
2024
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+24.23%
|
-
|
|
May 06
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
815
-1.29%
|
$11,410
$14.37 P/Share
|
|
Feb 29
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
243
-0.38%
|
$3,645
$15.25 P/Share
|
|
Feb 29
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
1,396
-0.58%
|
$20,940
$15.25 P/Share
|
|
Feb 27
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
1,091
-1.69%
|
$16,365
$15.58 P/Share
|
|
Feb 27
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
4,689
-1.92%
|
$70,335
$15.6 P/Share
|
|
Feb 26
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,015
-3.08%
|
$30,225
$15.9 P/Share
|
|
Feb 26
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
6,239
-2.49%
|
$93,585
$15.81 P/Share
|
|
Feb 24
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,848
+4.24%
|
-
|
|
Feb 24
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
11,762
+8.3%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 356K shares |
|---|
| Open market or private sale | 31.2K shares |
|---|